文献速递类风湿关节炎

培塞利珠单抗、阿巴西普、托珠单抗或积极传统治疗用于早期类风湿关节炎:研究者发起的随机对照NORD-STAR试验48周临床与影像学结果

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.
PubMed 文献 · Ann Rheum Dis · 2023-07-09

NORD-STAR试验将812例未治疗的中重度早期类风湿关节炎患者随机分入甲氨蝶呤联合积极传统治疗、培塞利珠单抗、阿巴西普或托珠单抗四组。48周时,阿巴西普组和培塞利珠单抗组的CDAI缓解率显著高于积极传统治疗组,托珠单抗组未达统计学显著;影像学进展低且组间无差异。

要点

  • 48周CDAI缓解率:阿巴西普59.3%、培塞利珠单抗52.3%、托珠单抗51.9%、积极传统治疗39.2%。
  • 与积极传统治疗相比,阿巴西普组缓解率调整差值+20.1%(p<0.001),培塞利珠单抗+13.1%(p=0.021),托珠单抗+12.7%(p=0.030)未达预设显著性水平。
  • 影像学进展低且组间无差异;严重不良事件比例分别为阿巴西普8.3%、培塞利珠单抗12.4%、托珠单抗9.2%、积极传统治疗10.7%。

核心结论

  • 与积极传统治疗相比,阿巴西普和培塞利珠单抗的临床缓解率更优,托珠单抗未显示优效。
  • 影像学进展低且各治疗组间相似。

研究设计与样本

  • 研究者发起的随机、评估者盲法研究,纳入未治疗的中重度疾病活动度早期类风湿关节炎患者。
  • 按1:1:1:1随机分配至甲氨蝶呤联合积极传统治疗(口服泼尼松快速减量至第36周停药,或柳氮磺吡啶、羟氯喹及肿胀关节腔内糖皮质激素注射)、培塞利珠单抗、阿巴西普或托珠单抗。
  • 共随机812例患者。
  • 共同主要终点为第48周临床疾病活动指数(CDAI)缓解(CDAI≤2.8)和影像学van der Heijde改良Sharp评分变化,采用逻辑回归和协方差分析估计,校正性别、抗瓜氨酸化蛋白抗体状态和国家。
  • 采用Bonferroni法和Dunnet法校正多重检验,显著性水平为0.025。

主要发现

  • 第48周校正后CDAI缓解率:阿巴西普59.3%、培塞利珠单抗52.3%、托珠单抗51.9%、积极传统治疗39.2%。
  • 与积极传统治疗相比,CDAI缓解率调整差值:阿巴西普+20.1%(p<0.001)、培塞利珠单抗+13.1%(p=0.021)、托珠单抗+12.7%(p=0.030)。
  • 关键次要临床结局在生物制剂组一致更优。
  • 影像学进展低,无组间差异。
  • 严重不良事件比例:阿巴西普8.3%、培塞利珠单抗12.4%、托珠单抗9.2%、积极传统治疗10.7%。

关键数值与推荐

  • CDAI缓解定义为CDAI≤2.8。
  • 多重检验校正采用Bonferroni法和Dunnet法,显著性水平为0.025。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal first-line treatment in early rheumatoid arthritis (RA) is debated. We compared clinical and radiographic outcomes of active conventional therapy with each of three biological treatments with different modes of action. METHODS: Investigator-initiated, randomised, blinded-assessor study. Patients with treatment-naïve early RA with moderate-severe disease activity were randomised 1:1:1:1 to methotrexate combined with (1) active conventional therapy: oral prednisolone (tapered quickly, discontinued at week 36) or sulfasalazine, hydroxychloroquine and intra-articular glucocorticoid injections in swollen joints; (2) certolizumab pegol; (3) abatacept or (4) tocilizumab. Coprimary endpoints were week 48 Clinical Disease Activity Index (CDAI) remission (CDAI ≤2.8) and change in radiographic van der Heijde-modified Sharp Score, estimated using logistic regression and analysis of covariance, adjusted for sex, anticitrullinated protein antibody status and country. Bonferroni's and Dunnet's procedures adjusted for multiple testing (significance level: 0.025). RESULTS: Eight hundred and twelve patients were randomised. Adjusted CDAI remission rates at week 48 were: 59.3% (abatacept), 52.3% (certolizumab), 51.9% (tocilizumab) and 39.2% (active conventional therapy). Compared with active conventional therapy, CDAI remission rates were significantly higher for abatacept (adjusted difference +20.1%, p<0.001) and certolizumab (+13.1%, p=0.021), but not for tocilizumab (+12.7%, p=0.030). Key secondary clinical outcomes were consistently better in biological groups. Radiographic progression was low, without group differences.The proportions of patients with serious adverse events were abatacept, 8.3%; certolizumab, 12.4%; tocilizumab, 9.2%; and active conventional therapy, 10.7%. CONCLUSIONS: Compared with active conventional therapy, clinical remission rates were superior for abatacept and certolizumab pegol, but not for tocilizumab. Radiographic progression was low and similar between treatments. TRIAL REGISTRATION NUMBER: NCT01491815.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Østergaard M, van Vollenhoven RF, Rudin A, et al. Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Ann Rheum Dis. 2023. PMID: 37423647. doi:10.1136/ard-2023-224116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。